In this Memorial Sloan Kettering series, 11 patients with metastatic DLL3-high pulmonary carcinoid received the DLL3/CD3 bispecific T-cell engager tarlatamab. Eight patients (73 percent) achieved an objective response; all had disease control and measurable tumor reduction, and only one had progressed at the time of data cutoff. Median progression-free survival was not reached. Cytokine-release syndrome was frequent during cycle 1 (82 percent), including two grade 3 events.
For CTSNet’s audience, this early but striking signal addresses a major unmet need in metastatic pulmonary carcinoid, where established systemic options often yield limited tumor responses. Tarlatamab is already approved in the United States for previously treated, extensive-stage small-cell lung cancer. This report suggests that DLL3-selected pulmonary carcinoid may represent another therapeutically actionable thoracic neuroendocrine tumor population, although prospective validation and careful toxicity management are essential.
